Management of the non-inducible patient.
Management of the patient without inducible arrhythmias is dictated by the clinical setting in which the arrhythmias occur. Decisions must be based on whether the patient is being treated for symptomatic arrhythmias, or is undergoing evaluation of risk for potentially lethal arrhythmias. The management is influenced by the anatomic substrate, as well as the clinical presentation. As with all diagnostic tests, the significance of the electrophysiology study depends on the clinical context, and this type of test reflects but one mechanism for tachycardia. Finally, it is critical to remember that the results of published clinical trials can be used to guide management decisions, only when the same stimulation protocol utilized in the trials is employed, and the patient has the same characteristics as those enrolled in the trial.
Buxton
Alfred E
AE
Cardiovascular Division, Department of Medicine, Brown Medical School, Providence, Rhode Island 09205, USA. Alfred_Buxton@Brown.edu
Kirk
Malcolm M
MM
Michaud
Gregory F
GF
Ellison
Kristin E
KE
Nyren
Laura
L
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D015716:Electrocardiography, Ambulatory; D022062:Electrophysiologic Techniques, Cardiac / Q000379:methods*; D005260:Female; D006323:Heart Arrest / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D008297:Male; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D013617:Tachycardia, Supraventricular / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D017180:Tachycardia, Ventricular / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents